Daneng Li, MD

home / authors / daneng-li-md

Articles

Choosing Second-Line Therapy for HCC After Atezolizumab/Bevacizumab

Choosing Second-Line Therapy for HCC After Atezolizumab/Bevacizumab

September 6th 2022

Daneng Li, MD, discusses potential second-line options following treatment with bevacizumab plus atezolizumab in patients with hepatocellular carcinoma.

Lenvatinib Shows Noninferior Survival Outcomes and Improved PFS in HCC

Lenvatinib Shows Noninferior Survival Outcomes and Improved PFS in HCC

February 23rd 2022

Daneng Li, MD, discusses the results of the REFLECT trial of lenvatinib in hepatocellular carcinoma.